Drug Trial Radar · NCT06425926
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
117
Planned (sponsor's estimate)
Start
May 9, 2024
Primary completion
Dec 2026
Study completion Nov 2027
Sponsor
- Lead sponsor
- Georgiamune IncIndustry
- Sponsor type
- Industry
- First posted
- May 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
Conditions
- Melanoma Stage IV
- Solid Tumor
Interventions
GIM-531Drug
GIM-531 administered orally daily
Anti-PD-1 monoclonal antibodyDrug
Continued treatment with anti-PD-1 therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs) / serious adverse events (SAEs) and tolerabilityTime frame: Through study completion, an average of 1 year
- Dose limiting toxicities (DLT) with GIM-531Time frame: 21 days
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona · Recruiting
Comprehensive Blood and Cancer Center
Bakersfield, California · Recruiting
Providence Medical Foundation
Fullerton, California · Recruiting
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
Los Angeles, California · Recruiting
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana
Billings, Montana · Recruiting
Weill Cornell Medicine - New York Presbyterian Hospital
New York, New York · Recruiting
University of Cincinnati Cancer Center
Cincinnati, Ohio · Recruiting
Tennessee Oncology, PLLC
Nashville, Tennessee · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.